Brief: Onxeo Reports DRIIV Phase 1 Study Of AsiDNA In Advanced Solid Tumors

Valerio Therapeutics SA

27/08/2020 17:09

Aug 27 (Reuters) - ONXEO SA  C4X.PA :
    * ONXEO REPORTS PUBLICATION OF FINAL RESULTS OF DRIIV PHASE
1
DOSE-ESCALATION STUDY OF ASIDNA™ IN ADVANCED SOLID TUMORS IN THE
BRITISH JOURNAL OF CANCER
    * DRIIV WAS INSTRUMENTAL IN DEMONSTRATING A GOOD SAFETY
PROFILE
AND ACTIVITY VIA IV ROUTE
    * THE ACTIVE DOSE OF 600 MG WAS DETERMINED TO BE THE OPTIMAL
DOSE
FOR USE IN COMBINATION

Source text for Eikon:  ID:nBwbm0YSDa 
Further company coverage:  C4X.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))